Difference between revisions of "Agomelatine-maprotiline"

From Psychiatrienet
Jump to: navigation, search
 
(3 intermediate revisions by 2 users not shown)
Line 2: Line 2:
 
| from = agomelatine  
 
| from = agomelatine  
 
| to = maprotiline  
 
| to = maprotiline  
| stop =  
+
| stop = {{StopAgomelatine}}
* Agomelatine can be stopped abruptly for every dosage.
+
| start =
| start =  
+
{{Inc25p3d2}}
 +
 
 +
|info =  
 
* A wash-out period is not necessary.
 
* A wash-out period is not necessary.
* Start administration of maprotiline the next day in a dosage of 25-75 mg/day.
 
* If necessary, increase dosage of maprotiline.
 
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
 
 
}}
 
}}

Latest revision as of 10:40, 21 October 2015

Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from agomelatine to maprotiline.[1] [2]

Nietinrijdenbord.png Stop agomelatine
  • Day 1: Stop agomelatine.
  • Agomelatine can be stopped abruptly for every dosage.[3]
Eenrichtingbord.png Start maprotiline
  • Day 2: Start with normal dosage and increase with about 25% (up to 50%) every 3 days to target dose.
Infobord.png More information
  • A wash-out period is not necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.